Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss
NCT ID: NCT06484634
Last Updated: 2024-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
175 participants
INTERVENTIONAL
2023-12-01
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths
NCT03601338
Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy
NCT00721591
Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
NCT04621773
The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage
NCT03209063
Timing of Initiation of LMWH Administration in Pregnant Women With APS
NCT02326051
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LMWH Group
Women received a daily dose of 40 mg of Low Molecular Weight Heparin subcutaneously.
Low molecular weight heparin
A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
Control
Women received the placebo in the form of a multivitamin tablet.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low molecular weight heparin
A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age above 8 weeks
* A history of ≥3 consecutive first trimester pregnancy losses
Exclusion Criteria
* Positive IgG and IgM anticardiolipin antibodies
* Positive for thrombophilia screening
* Any platelet function abnormality or a previous thromboembolic event requiring anticoagulant therapy (including heparin, aspirin or warfarin)
* Sensitive to acetylsalicylic acid, heparin, or warfarin
* Patients with any genetic, anatomical, or hormonal cause of recurrent pregnancy loss
18 Years
44 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RESnTEC, Institute of Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DG Khan Hospital
Dera Ghazi Khan, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LMWHDGKHAN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.